Why We’re Doubling Down on Kanvas
At Pangaea Ventures, we invest in bold hard tech innovations reshaping the future of industry and solving our planet’s (and its people’s) most pressing challenges. Kanvas Biosciences is a quintessential example leveraging groundbreaking spatial biology technology and precision microbiome therapeutics to address untapped opportunities in medicine and beyond.
Our belief in Kanvas was strong at the time of our original investment in 2024, and it is even stronger today as we affirm our participation in their $48M Series A. Co-led by existing investors DCVC, Lions Capital LLC, and alongside others like Gates Foundation, ATHOS KG, Germin8, and Ki Tua Fund, we’re proud to continue to support this journey.
Here is why we invested, again.
Opportunity
Globally, the human microbiome is rapidly gaining recognition as a key to unlocking novel therapies and health interventions. Yet, understanding these diverse microbial communities, and therapeutically targeting them with precision, has proven challenging. Kanvas is uniquely positioned with three platforms that address this challenge. Spatial biology is a market that has seen accelerated growth given the rise of AI and ability to handle large data sets (Ex. 4TB per experiment for Kanvas) with varying market size estimations ranging from $239M - $860M in 2022-2024 with a CAGR ranging from 12.3% - 21% between 2027 and 2031; the microbiome manufacturing market for live biotherapeutics is estimated to be worth $27M in 2023, and is expected to grow at a CAGR of 17% between 2023 and 2035; meanwhile, the live biotherapeutics (LBP) market was estimated in 2021 to be at $355.9M, with an expected CAGR of 25.2% from then until 2030. These markets at first pass might seem small, but this is due to the limited success in the field to date, and the need for the right tools and technology to enable progress. Kanvas’s HIPR-FISH technology unlocks this path for corporates and startup companies in this market.
The urgent need for new solutions is driven by rising rates of cancer, inflammatory bowel disease, and metabolic disorders, combined with the limitations of conventional therapies.
Kanvas Biosciences is answering this call. Their drug discovery and manufacturing platform is uniquely capable of mapping host-microbiome interactions, profiling gene expression, and manufacturing complex consortia (hundreds of microbes working synergistically) to restore health. This technical depth positions Kanvas alone at the forefront of microbiome-based precision medicine.
Tackling Drug Discovery’s Toughest Biological Challenge
For conditions ranging from ICI-refractory cancers to inflammatory and metabolic diseases, the role of the microbiome is only starting to be understood. Kanvas’s proprietary HiPR-Map spectral imaging technology enables detailed, spatial visualization of microbial communities and their exact interactions with host cells.
Further, Kanvas’s manufacturing capabilities allow them to produce precisely defined microbial consortia, something most competitors struggle to scale beyond simple single strain therapies or variable fecal transplants. Their lead clinical candidates, KAN-001 and KAN-004, are designed to maximize immunotherapy efficacy in solid organ cancers and prime patient response to immune checkpoint inhibitors and reduce the debilitating side effects of these drugs on patients requiring them to stop treatment, respectively.
Impact and Industry Validation
The significance of Kanvas’s platform extends far beyond drug discovery. With applications in agriculture, food safety, and diagnostics, the technology is poised for broad impact. Recent partnerships, ongoing clinical pipeline development, and expanding in South San Francisco facilities to be capable of GMP manufacturing demonstrates Kanvas’s momentum and forward-thinking approach.
Now working with the Gates Foundation, Kanvas will apply its microbiome platform to a therapy for malnutrition in women and children, the most vulnerable population, focusing from the outset on how to deliver such a complex treatment in an affordable way at scale.
Why We Invested
Pioneering Hard Tech: Kanvas’s spatial biology engine and proprietary imaging tools reflect deep scientific rigor and transformative potential, core to our vision of investing for long-term transformative health impact.
Rapidly Expanding Markets: As major clinical milestones fuel attention and investment in Live biotherapeutic products (LBPs), Kanvas is strongly positioned for growth in multiple expanding markets.
Tangible Impact: With every clinical trial, every new partnership, and every new innovation, Kanvas's technology brings us closer to safer, more effective therapies for cancer and other challenging diseases and enables new frontiers in diagnostics and agricultural biotech.
Exceptional Leadership: Since our first discovery call in December 2022, Kanvas’s leadership team has instilled confidence through their intelligence, responsiveness, strategic foresight, and their ability to keep the entire organization laser-focused on executing their vision. Our belief in Matt and the team's ability to execute is immense.
Looking Forward
Kanvas Biosciences is redefining what’s possible for microbiome drug development, diagnostics, and biomanufacturing. Their ability to generate actionable insights and scale complex LBPs is driving new standards of precision, efficacy, and commercial viability. We are proud to stand with Kanvas as they move from visionary science to real-world impact.